Want to see HK:6978 full AI Analyst Report?
Immunotech Biopharm Ltd (6978) AI Stock Analysis
Top Page
Immunotech Biopharm Ltd
(HKEX:6978)
The score is primarily constrained by severe financial weaknesses, including pre-revenue status, negative equity, persistent losses, and cash burn. Weak technical momentum and an unsupportive valuation further limit the score, despite narrowing losses and reduced debt.
Immunotech Biopharm Ltd (6978) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 222.30M
- Dividend Yield
- ―
- Average Volume (3M)
- 104.08K
- Price to Earnings (P/E)
- -1.1
- Beta (1Y)
- 0.64
- Revenue Growth
- ―
- EPS Growth
- 21.82%
- Country
- Hong Kong
- Employees
- 189
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immunotech Biopharm Ltd Business Overview & Revenue Model
Company Description
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers wi...
Immunotech Biopharm Ltd Financial Statement Overview
Summary
Pre-revenue operations, persistent losses, negative equity, ongoing cash burn, and funding reliance create severe financial risk. Reduced debt and narrowing losses provide limited support.
Income Statement
15Very NegativeBalance Sheet
25NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -49.84M | -53.87M | 0 | 0 | 0 | 0 |
| EBITDA | -104.84M | -168.80M | -140.03M | -177.65M | -230.15M | -324.33M |
| Net Income | -168.89M | -230.78M | -186.91M | -334.82M | -318.11M | -354.22M |
Balance Sheet | ||||||
| Total Assets | 479.75M | 603.20M | 564.04M | 846.28M | 879.44M | 1.10B |
| Cash, Cash Equivalents and Short-Term Investments | 65.93M | 154.63M | 57.49M | 176.97M | 79.46M | 353.34M |
| Total Debt | 402.12M | 440.26M | 384.56M | 784.01M | 149.81M | 111.05M |
| Total Liabilities | 566.91M | 569.01M | 580.50M | 675.39M | 373.07M | 274.51M |
| Stockholders Equity | -83.78M | -13.93M | -13.30M | 173.62M | 508.44M | 822.26M |
Cash Flow | ||||||
| Free Cash Flow | -135.97M | -111.92M | -153.81M | -186.17M | -277.49M | -435.89M |
| Operating Cash Flow | -120.53M | -97.29M | -125.74M | -163.63M | -180.92M | -254.65M |
| Investing Cash Flow | -1.20M | -98.07M | 141.10M | -116.60M | 23.38M | -328.21M |
| Financing Cash Flow | 161.74M | 203.20M | -20.59M | 273.92M | -36.06M | -11.00M |
Immunotech Biopharm Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6978, the sentiment is Negative. The current price of 0.36 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.39, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.36 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6978.
Immunotech Biopharm Ltd Peers Comparison
Overall Rating
HK:218157Neutral
HK:212649Neutral
HK:213742Neutral
HK:249641Neutral- HK:697839Underperform
HK:662837Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2181 | 57Neutral | HKD 1.79B | 17.80 | 48.25% | ― | 88.38% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2126 | 49Neutral | HKD 925.48M | -2.35 | -66.16% | ― | 67.48% | 43.84% |
| HK:2137 | 42Neutral | HKD 708.65M | -3.48 | -7.32% | ― | ― | 51.71% |
| HK:2496 | 41Neutral | HKD 1.05B | -13.87 | 85.52% | ― | -55.22% | 57.76% |
| HK:6978 | 39Underperform | HKD 222.30M | -1.09 | 345.69% | ― | ― | 21.82% |
| HK:6628 | 37Underperform | HKD 327.59M | -1.65 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6978 | Immunotech Biopharm Ltd | 0.36 | -2.94 | -89.09% | |
| HK:2137 | Brii Biosciences Limited | 0.98 | -0.91 | -48.15% | |
| HK:2126 | JW (Cayman) Therapeutics Co. Ltd. | 2.22 | -1.82 | -45.05% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:6628 | Transcenta Holding Limited | 0.73 | -2.31 | -75.90% | |
| HK:2496 | Wuhan YZY Biopharma Co., Ltd. Class H | 4.00 | -3.01 | -42.94% |
Immunotech Biopharm Ltd Corporate Events
Immunotech Biopharm Seeks HK$37 Million via Share Placement to Fund R&D
Immunotech Biopharm Ltd has entered into a placing agreement to issue up to 123,500,160 new shares, representing 20% of its existing share capital. The shares will be placed at no less than HK$0.300 each through Maxa Asset Management Limited on a bes...
Immunotech Biopharm Updates Commercialisation Timeline for Core Cell Therapy EAL®
Immunotech Biopharm has issued a supplemental announcement to its 2025 annual report, updating investors on the expected commercialisation timeline for its core product EAL®, a non-genetically modified cell therapy for preventing postsurgical li...
Immunotech Biopharm Narrows Interim Loss But Net Liabilities Deepen
Immunotech Biopharm Ltd, a Chinese biopharmaceutical group, concentrates on T cell-based cellular immunotherapies for cancer, anchored by its core product candidate EAL. The firm has developed a proprietary technology platform for EAL production, str...
Immunotech Biopharm Sets August Board Meeting to Approve Interim Results
Immunotech Biopharm Ltd has scheduled a board meeting for 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The planned publication of these interim results will provide investors and other stakeholders w...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026